Wegovy's Super-Dose: A New Frontier in Weight Loss Unveiled
- A higher 7.2 mg dose of Wegovy® led to a groundbreaking average weight loss of nearly 21% in a major clinical trial1, 2.
- An astonishing one-third of participants on the new dose shed 25% or more of their body weight, a result previously unimaginable for many1, 5.
- The results, presented at the prestigious American Diabetes Association (ADA) Scientific Sessions, signal a potential paradigm shift in obesity treatment6.
In a stunning revelation that could reshape the fight against obesity, Novo Nordisk has unveiled game-changing results for a higher dose of its blockbuster drug, Wegovy®. Data from the STEP UP trial, presented to a packed audience at the ADA Scientific Sessions, showed that a new 7.2 mg dose of semaglutide delivered an average body weight loss of 20.7% over 72 weeks—shattering previous records1.
The results are staggering. While the standard 2.4 mg dose is already highly effective, this higher dose pushes the boundaries of what’s possible with medication. The most dramatic finding: a full third of participants on the 7.2 mg dose lost a quarter or more of their body weight, a life-altering outcome that rivals the results of some bariatric surgeries1, 5. For comparison, virtually no one in the placebo group achieved this milestone.
"The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen," said lead study author Sean Wharton, calling it another powerful option for patients1.
These findings go beyond the scale, building on semaglutide's proven benefits for heart, liver, and joint health1. While gastrointestinal side effects were the most common issue, they were largely mild to moderate and consistent with the drug class, with a low discontinuation rate5.
As Novo Nordisk pioneers an oral version of Wegovy and prepares to file for a label update, these results herald a new, more potent era in medical weight management, offering profound hope to millions.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.